Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Non-valvular Atrial Fibrillation

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02488421

CV185-371

Details and patient eligibility

About

The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.

Full description

Actual number of patients enrolled for UK : 15242 patients

Actual number of patients enrolled for Germany : 22880 patients

Enrollment: 38,122 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have an apixaban, rivaroxaban, dabigatran or VKA prescription during the study period
• Are ≥18 years old at index date
• Have ≥12 months of computerised medical data prior to index date
• Have a record of AF on or ever prior to index date (index OAC prescription)

Exclusion criteria

• Have a record for a valvular condition (ie, rheumatic valvular disease and prosthetic valves) on or ever prior to index date
• Have a history (ever prior to index date) of the Oral anticoagulant (OACs) which are prescribed during the study period

Trial design

38,122 participants in 4 patient groups

Patient treated with Apixaban

Patient treated with Rivaroxaban

Patient treated with Dabigatran

Patient treated with vitamin K antagonists